Drugs / Pudafensine
Pudafensine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05728671 | Feb → May 2023 | — | Initiator Pharma | Unknown | No outcome recorded |
| Phase 1 | NCT05181852 | Jan → May 2022 | — | Initiator Pharma | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07391241 | Dec 2025 → Sep 2026 expected | vulvodynia | Initiator Pharma | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pudafensine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07391241 ↗ |
| Known as | IP2015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05728671 ↗ |
| Known as | IP2015 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068030 ↗ |
| Known as | NS-18313 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068030 ↗ |
| Known as | Pudafensina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068030 ↗ |
| Modality | Small molecule | — CHEMBL6068030 ↗ |
| Route | Oral | “two single oral dose levels of IP2015” NCT05181852 ↗ |